Disease Outcome of Ulcerative Colitis in an Era of Changing Treatment Strategies: Results from the Dutch Population-Based IBDSL Cohort

Autor: Steven Jeuring, Ton Ambergen, Wim Hameeteman, Mariëlle Romberg-Camps, Stephanie O. Breukink, Liekele E. Oostenbrug, Tim van den Heuvel, Ad A.M. Masclee, Daisy Jonkers, Ad A. van Bodegraven, Paul Bours, Laurents P. S. Stassen, Maurice P. Zeegers, Marieke Pierik
Přispěvatelé: Interne Geneeskunde, Complexe Genetica, FHML Methodologie & Statistiek, Surgery, RS: CAPHRI School for Public Health and Primary Care, RS: NUTRIM - R2 - Gut-liver homeostasis, RS: CAPHRI - R1 - Ageing and Long-Term Care, RS: SHE - R1 - Research (OvO)
Rok vydání: 2015
Předmět:
Zdroj: Journal of Crohn's & Colitis, 9(10), 837-845. Oxford University Press
ISSN: 1876-4479
1873-9946
DOI: 10.1093/ecco-jcc/jjv129
Popis: Background and Aims: In the past decades, treatment options and strategies for ulcerative colitis [UC] have radically changed. Whether these developments have altered the disease outcome at population level is yet unknown. Therefore, we evaluated the disease outcome of UC over the past two decades in the South-Limburg area of The Netherlands. Methods: In the Dutch population-based IBDSL cohort, three time cohorts were defined: cohort 1991-1997 [cohort A], cohort 1998-2005 [cohort B], and cohort 2006-2010 [cohort C]. The colectomy and hospitalisation rates were compared between cohorts by Kaplan-Meier survival analyses. Hazard ratios [HR] for early colectomy [within 6 months after diagnosis], late colectomy [beyond 6 months after diagnosis], and hospitalisation were calculated using Cox regression models. Results: In total, 476 UC patients were included in cohort A, 587 patients in cohort B, and 598 patients in cohort C. Over time, an increase in the use of immunomodulators [8.1%, 22.8% and 21.7%, respectively, p
Databáze: OpenAIRE